Innovation
Three looks at how AI may change retinal practice
Artificial intelligence models have shown the potential to decrease disparities in diabetic eye care, personalize management for nAMD treatment and predict outcomes for CRVO.
Pipeline Report: New entries continue to exceed exits
Exits for discontinued programs (three over two years) exceed exits for approvals (two).
Why not vitrectomy for vitreous opacities?
Why pars plana vitrectomy has come of age for vitreous opacities in selected patients.
The robots are coming to retina
An update of the science behind robotic-assisted vitreoretinal surgery and its potential future applications.
Two tales of DR progression
Clinical trials show encouraging outcomes for treating diabetic retinopathy progression, but the real-world evidence tells a different story.
Five things to know about biosimilars in retina
A primer on the review and approval processes as the first anti-VEGF biosimilar prepares for launch in 2022.
Mixed results in DME, PDR hemorrhage, ROP
Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.
Retinal implant platforms moving from uveitis to AMD
Treatments show potential for various posterior-segment diseases based on their success treating noninfectious uveitis.
Five emerging treatments show mixed results
Uncertainty about PVL for VMT and aflibercept for NPDR, some clarity on PDT, and early promise for stem cells and a bioresorbable implant.
Ocular gene therapy: The next generation
Emerging viral and synthetic vectors along with newer delivery platforms are poised to broaden genetic treatments in retina.
AI in retina: Ready for prime time?
Artificial intelligence is ready to be incorporated into retina referral networks. Here’s a look at the state of the science.
Five evidence-based answers for PVD, retinal breaks
Answers to commonly encountered clinical questions about the clinical course of posterior vitreous detachment and symptomatic retinal breaks.
Many new entries, but no impactful exits
The list grows longer with new entries and categories and no trials resulting in approvals.
The latest in AI for managing DR
In ongoing investigations, artificial intelligence platforms have shown strong sensitivity and specificity in monitoring diabetic retinopathy.
Genetics, Vitamins And Astronaut Eyes
How space research is providing new insights into ophthalmic pathophysiology with implications for terrestrial and aerospace medicine.
Argus II in the Real World
Experience with six patients who have had this device implanted.
An App to Monitor Patients At Home
Mobile system can alert retina specialists to vision changes before patients can.
Big Data and AMD Progression
Gathering and analyzing imaging biomarkers from SD-OCT along with other inputs can aid in tracking patients.
10 Abstracts Worth a Second Look
A review of compelling presentations in retina from ARVO.
Experience of 50 Vitrectomies with EVA
Smooth transition between vacuum and flow modes.
Current Issue
Continuing Medical Education
Additional Publications
Earlier Treatment Can Matter for Macular Edema Following Retinal Vein Occlusion
Sponsored by Regeneron
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
In pivotal trials, Eylea demonstrated its efficacy as a powerful treatment option for macular edema following RVO.
Treating Chronic Inflammation Associated With Uveitis Affecting the Posterior Segment in a Retina Setting with YUTIQ
GA: Recognizing the Burden
Treatment of Proliferative Diabetic Retinopathy
Improving Wet AMD Outcomes With a Fellow Eye Strategy
Eyepoint Yutiq: A Discussion Among Experts on the Treatment of Uveitis Affecting the Posterior Segment
